p>This test method is one of a series of tests listed in Practice F 748 and ISO 10993-4 to assess the biocompatibility of materials contacting blood in medical applications.

This test method is similar to Practice F 756 but modified to accommodate nanoparticulate materials.

1. Scope

1.1 This test method covers assessing the effect of nanoparticulate materials on the integrity of red blood cells.

1.2 This test method uses diluted whole blood incubated with nanoparticulate material and the hemoglobin released from damaged red blood cells is determined.

1.3 This test method is similar to Practice F 756 with the volumes reduced to accommodate nanoparticulate material.

1.4 This test method is part of the in-vitro preclinical characterization and is important for nanoparticulate material that will contact the blood in medical applications.

1.5 The values given in SI units are to be considered as the standard.

1.6 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

2. Referenced Documents (purchase separately) The documents listed below are referenced within the subject standard but are not provided as part of the standard.

ASTM Standards

F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices

F756 Practice for Assessment of Hemolytic Properties of Materials

F1877 Practice for Characterization of Particles

F1903 Practice for Testing For Biological Responses to Particles In Vitro

ISO Standard

Keywords

hemolysis; nanoparticulate; plasma; whole blood;

ICS Code

ICS Number Code 11.040.20 (Transfusion, Infusion); 71.100.01 (Products of the chemical industry in general)

Citing ASTM Standards

[Back to Top]